Logo
x

Search

Subscribe Now

nda

Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis

Amylyx Submits NDA to the US FDA for AMX0035 to Treat Amyotrophic Lateral Sclerosis

  • November 3, 2021
Incyte Reports the US FDA's Acceptance of NDA for Parsaclisib to Treat R/R Non-Hodgkin Lymphomas

Incyte Reports the US FDA's Acceptance of NDA for Parsaclisib to Treat R/R Non-Hodgkin Lymphomas

  • November 1, 2021
Innovent Reports NMPA's Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Innovent Reports NMPA's Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

  • September 23, 2021
Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency

Agios Reports the US FDA's Acceptance of NDA and Priority Review for Mitapivat to Treat Pyruvate Kinase Deficiency

  • August 18, 2021
Ipsen Reports the Withdrawal of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva

Ipsen Reports the Withdrawal of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva

  • August 13, 2021
Dermavant Reports the US FDA's Acceptance of NDA for Tapinarof Cream to Treat Plaque Psoriasis

Dermavant Reports the US FDA's Acceptance of NDA for Tapinarof Cream to Treat Plaque Psoriasis

  • August 11, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.